Monnier, L., Colette, C., Schlienger, J.L., Bauduceau, B., D.R.O., Glucocentric risk factors for macrovascular complications in diabetes: Glucose “legacy” and “variability”-what we see, know and try to comprehend. Diabetes Metab 45 (2019), 401–408.
Scheen, A.J., Charbonnel, B., Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal. Diabetes Metab 40 (2014), 176–185.
Scheen, A.J., Cardiovascular outcome studies in type 2 diabetes: comparison between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes Res Clin Pract 143 (2018), 88–100.
Davies, M.J., D'Alessio, D.A., Fradkin, J., Kernan, W.N., Mathieu, C., Mingrone, G., et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61 (2018), 2461–2498.
Scheen, A.J., Diabetes research & clinical practice series: implications of the recent CVOTs in type 2 diabetes: impact on guidelines: the endocrinologist point of view. Diabetes Res Clin Pract, 2019, 10.1016/j.diabres.2019.05.005 Epub:May 17. pii: S0168-8227(19)30607-2 [Epub ahead of print].
Scheen, A.J., Effects of glucose-lowering agents on renal surrogate endpoints and hard clinical outcomes in patients with type 2 diabetes. Diabetes Metab 45 (2019), 110–121.
Das, S.R., Everett, B.M., Birtcher, K.K., Brown, J.M., Cefalu, W.T., Januzzi, J.L. Jr., et al. 2018 ACC Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 72 (2018), 3200–3223.
Cosentino, F., Ceriello, A., Baeres, F.M.M., Fioretto, P., Garber, A., Stough, W.G., et al. Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. Eur Heart J 40 (2019), 2907–2919.
Arnett, D.K., Blumenthal, R.S., Albert, M.A., Buroker, A.B., Goldberger, Z.D., Hahn, E.J., et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 74 (2019), 1376–1414.
Cosentino, F., Grant, P.J., Aboyans, V., Bailey, C.J., Ceriello, A., Delgado, V., et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboation with the EASD. Eur Heart J, 2019, 10.1093/eurheartj/ehz486 pii: ehz486 [Epub ahead of print].
Valensi, P., Picard, S., Pathak, A., Type 2 diabetes: Why should diabetologists and cardiologists work more closely together?. Diabetes Metab, 2019, 10.1016/j.diabet.2019.07.007 pii: S1262-3636(19)30119-3 [Epub ahead of print].
Einarson, T.R., Acs, A., Ludwig, C., Panton, U.H., Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol, 17, 2018, 83.
Rawshani, A., Rawshani, A., Franzen, S., Sattar, N., Eliasson, B., Svensson, A.M., et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 379 (2018), 633–644.
Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
Arnold, S.V., de Lemos, J.A., Rosenson, R.S., Ballantyne, C.M., Liu, Y., Mues, K.E., et al. Use of guideline-recommended risk reduction strategies among patients with diabetes and atherosclerotic cardiovascular disease. Circulation 140 (2019), 618–620.
Scheen, A.J., GLP-1 receptor agonists and cardiovascular protection: Class effect or not?. Diabetes Metab 44 (2018), 193–196.
Kristensen, S.L., Rorth, R., Jhund, P.S., Docherty, K.F., Sattar, N., Preiss, D., et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7 (2019), 776–785.
Scheen, A.J., Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. Circ Res 122 (2018), 1439–1459.
Zelniker, T.A., Wiviott, S.D., Raz, I., Im, K., Goodrich, E.L., Bonaca, M.P., et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393 (2019), 31–39.
Perkovic, V., Jardine, M.J., Neal, B., Bompoint, S., Heerspink, H.J.L., Charytan, D.M., et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380 (2019), 2295–2306.
Bonnet, F., Scheen, A.J., Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: potential contribution for diabetic complications and cardiovascular disease. Diabetes Metab 44 (2018), 457–464.
Zelniker, T.A., Wiviott, S.D., Raz, I., Im, K., Goodrich, E.L., Furtado, R.H.M., et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation 139 (2019), 2022–2031.
Wiviott, S.D., Raz, I., Bonaca, M.P., Mosenzon, O., Kato, E.T., Cahn, A., et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380 (2019), 347–357.
Gerstein, H.C., Colhoun, H.M., Dagenais, G.R., Diaz, R., Lakshmanan, M., Pais, P., et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394:10193 (2019), 121–130.
Scheen, A.J., Why not adding a glucose-lowering agent with proven cardioprotection in high-risk patients with type 2 diabetes at HbA1c target on metformin?. Diabetes Res Clin Pract 147 (2019), 169–171.
Inzucchi, S.E., Kosiborod, M., Fitchett, D., Wanner, C., Hehnke, U., Kaspers, S., et al. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation 138 (2018), 1904–1907.
Heerspink, H.J., Desai, M., Jardine, M., Balis, D., Meininger, G., Perkovic, V., Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 28 (2017), 368–375.
Cooper, M.E., Inzucchi, S.E., Zinman, B., Hantel, S., von Eynatten, M., Wanner, C., et al. Glucose control and the effect of empagliflozin on kidney outcomes in type 2 diabetes: an analysis from the EMPA-REG OUTCOME trial. Am J Kidney Dis 74 (2019), 713–715.
McMurray, J.J.V., Solomon, S.D., Inzucchi, S.E., Kober, L., Kosiborod, M.N., Martinez, F.A., et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med, 2019, 10.1056/NEJMoa1911303 [Epub ahead of print].
Crowley, M.J., Williams, J.W. Jr., Kosinski, A.S., D'Alessio, D.A., Buse, J.B., Metformin use may moderate the effect of DPP-4 Inhibitors on cardiovascular outcomes. Diabetes Care 40 (2017), 1787–1789.
Prospective Diabetes Study (UKPDS) U.K. Group, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998), 854–865.
Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A., 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.
Boussageon, R., Supper, I., Bejan-Angoulvant, T., Kellou, N., Cucherat, M., Boissel, J.P., et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med, 9, 2012, e1001204.
Griffin, S.J., Leaver, J.K., Irving, G.J., Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia 60 (2017), 1620–1629.
Han, Y., Xie, H., Liu, Y., Gao, P., Yang, X., Shen, Z., Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol, 18, 2019, 96.
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., Viollet, B., Metformin: from mechanisms of action to therapies. Cell Metab 20 (2014), 953–966.
Zilov, A.V., Abdelaziz, S.I., AlShammary, A., Al Zahrani, A., Amir, A., Assaad Khalil, S.H., et al. Mechanisms of action of metformin with special reference to cardiovascular protection. Diabetes Metab Res Rev, 35, 2019, e3173.
Scheen, A.J., Paquot, N., Metformin revisited: A critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab 39 (2013), 179–190.
Bromage, D.I., Yellon, D.M., The pleiotropic effects of metformin: time for prospective studies. Cardiovasc Diabetol, 14, 2015, 109.
Luo, F., Das, A., Chen, J., Wu, P., Li, X., Fang, Z., Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management. Cardiovasc Diabetol, 18, 2019, 54.
Yu, H., Zhong, X., Gao, P., Shi, J., Wu, Z., Guo, Z., et al. The potential effect of metformin on cancer: an umbrella review. Front Endocrinol (Lausanne), 10, 2019, 617.
Soukas, A.A., Hao, H., Wu, L., Metformin as anti-aging therapy: is it for everyone?. Trends Endocrinol Metab 30 (2019), 745–755.
Maruthur, N.M., Tseng, E., Hutfless, S., Wilson, L.M., Suarez-Cuervo, C., Berger, Z., et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 164 (2016), 740–751.
Inzucchi, S.E., Is it time to change the type 2 diabetes treatment paradigm? No! Metformin should remain the foundation therapy for type 2 diabetes. Diabetes Care 40 (2017), 1128–1132.
Harrington, J.L., de Albuquerque Rocha, N., Patel, K.V., Verma, S., McGuire, D.K., Should metformin remain first-line medical therapy for patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease? An alternative approach. Curr Diabetes Rep, 18, 2018, 64.
